Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in New York

FOR IMMEDIATE RELEASE

Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in New York

Contact: Patricia Pearson, ppearson@ubivac.com

March 27, 2017

Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 5th Annual Sachs Cancer Biopartnering and Investment Forum on March 28 in New York.

During his remarks, Dr. Fox will detail UbiVac’s DRibble immunotherapy (DPV-001), a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. DRibble vaccines are a disruptive technology able to overcome tolerance and induce or boost broad anti-cancer immunity. Since a pre-existing anti-cancer immune response is required for response to checkpoint blockade, UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy providing a needed component to boost effectiveness of the pipeline of co-stimulatory and checkpoint antibodies that are approved or currently under development.

DPV-001 recently completed an NCI-supported randomized multi-center Phase II clinical trial as adjuvant therapy for non-small cell lung cancer. Results of that study were presented at the World Lung Cancer Conference in December 2016.

This week Dr. Fox will outline positive results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). “We are excited that early results document the ability of DPV-001 to educate patients’ immune system so they can recognize their cancer, Dr. Fox said.

The Sachs Forum, www.sachsforum.com is a yearly gathering of thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical and biotechnology firms designed to facilitate partnering, funding and investment. The meeting is expected to include about 200 delegates. Tracks will include presentations by both listed and private biotechnology companies.

Sachs Associates is considered to have significant knowledge of key individuals operating within the European and global biotech field, putting the firm at the forefront of the industry and, through the Forum, providing an effective platform for companies like UbiVac to increase recognition among collaborators and funders.

Award Number R44CA121612 from the National Cancer Institute supports the research and clinical trial of DPV-001 in patients with NSCLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 recently completed a Phase II randomized multi-center adjuvant study for non-small cell lung cancer that documented efficacy for induction or boosting of broad anti-cancer immunity. Based on these data UbiVac is planning to open a phase Ib/II study of DPV-001 + anti-OX40 in patients with advanced cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.

Bernie Fox